Association of Hippocampal Subfields, CSF Biomarkers, and Cognition in Patients With Parkinson Disease Without

Sara Becker1, Oliver Granert2, Maarten Timmers2

  • 1From the Department of Neurodegenerative Diseases (S.B., B.R., I.L.-S.), Hertie Institute for Clinical Brain Research; German Center for Neurodegenerative Diseases (S.B., B.R., I.L.-S.), Tübingen; Department of Neurology (O.G., W.M., D.B.), Christian-Albrechts-University, Kiel, Germany; Janssen Research and Development, a Division of Janssen Pharmaceutica N.V. (M.T., L.V.N., J.S.), Beerse; Reference Center for Biological Markers of Dementia (M.T.), Institute Born-Bunge, University of Antwerp, Belgium; Department of Clinical and Experimental Sciences (A.P.), University of Brescia; Parkinson's Disease Rehabilitation Centre (A.P.), FERB ONLUS Sant'Isidoro Hospital, Trescore Balneario, Italy; Janssen Research and Development LLC (G.S., W.R.G.), Titusville, NJ; Translational Medicine Neuroscience (J.S.), UCB Biopharma SPRK, Braine-l'Alleud, Belgium; Magnetic Resonance Center (K.S.), Max Planck Institute for Biological Cybernetics; and Department of Biomedical Magnetic Resonance (K.S.), University Hospital Tübingen, Germany. sara.becker@med.uni-tuebingen.de.

Neurology
|November 21, 2020
PubMed
Abstract